Immune function evaluation (immuknow assay) in a patient treated with infliximab who developed miliary histoplasmosis

Infectious Diseases in Clinical Practice

Volumn 13, Issue 6, 2005, Pages 315-317

  Yan, Tom D ^a   Kavuru, Mani S ^a   Yen Lieberman, Belinda ^a   Brzezinski, Aaron ^a   Gordon, Steve M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIBODY; AZITHROMYCIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CEFTRIAXONE; COMPLEMENT FIXING ANTIBODY; INFLIXIMAB; ITRACONAZOLE; MICROSOMAL AMINOPEPTIDASE; MOXIFLOXACIN; TUBERCULIN;

ADULT; ARTICLE; BACTERIUM; BRONCHITIS; BRONCHOSCOPY; CASE REPORT; COMPLEMENT FIXATION; COUGHING; CROHN DISEASE; ENTERITIS; FEVER; FUNGUS; GENERAL ASPECTS OF DISEASE; HISTOPLASMOSIS; HUMAN; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOREACTIVITY; LUNG GRANULOMA; LUNG INFILTRATE; LYMPHOCYTE; MALAISE; MALE; PNEUMONIA; TACHYCARDIA; TACHYPNEA; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 28044436912     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000166939.85131.e8     Document Type: Article

References (6)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with Infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
2. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279-1282.
3. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonist. Clin Infect Dis. 2004;38:1261-1265.
4. Schulick RD, Weir MB, Miller MW, et al. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation. 1993;56:590-596.
5. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-78.
6. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15(4):463-473.